KRAS and colorectal carcinoma: However, the combination of KRASG12C inhibitors with EGFR blockers such as cetuximab increased response rates and extended patient survival beyond the effect of KRAS inhibitors in monotherapy, ultimately granting accelerated FDA approval of adagrasib plus cetuximab for KRASG12C‐mutated CRC [12].